Liam Gallagher's clothing brand Pretty Green has called in advisers as it struggles with the challenges facing the UK's high street.

The clothing label has appointed Moorfields Advisory to review a range of options, just months after it took a hit from the collapse of House of Fraser.

Pretty Green has 12 stores across the UK including in Glasgow and sold at concessions in several House of Fraser department stores, as well as online.

Singer Mr Gallagher is its largest shareholder.

In August it was left out of pocket from the administration of House of Fraser, becoming one of hundreds of suppliers to lose money in the chain's collapse.

READ MORE: Chef Mark Greenaway reveals new Edinburgh venture

The retailer had debts of close to £1 billion when it went under.

Advisers from Moorfields said in a statement that Pretty Green, which is named after a song by The Jam, had also been affected by the weaker retail environment.

"Pretty Green is not immune to the challenges facing the UK high street as customers migrate from purchasing in store to online," a spokeswoman said.

"The growing overall demand for the brand, coupled with a strong online customer base, position the company well to navigate these changes and we are therefore considering all options."

The company's turnover jumped to £38.2 million in the 16 months to January 2018.

Pre-tax losses narrowed to £1.5m from a £5.6m loss.

Outsourcer Serco has won a 200 million US dollar (£153.1 million) contract to provide support to field workers for a US government pension agency.

As part of the contract, Serco will help field officers of the Pension Benefit Guaranty Corporation (PBGC) manage documents and records, build databases and administer benefits.

PBGC protects the retirement incomes of nearly 37 million Americans in private sector defined benefit pension plans and is responsible for the benefits of about 1.5 million people in failed pension schemes.

READ MORE: Debenhams shares spike on Mike Ashley's attempted coup

Serco's chief Rupert Soames said the contract strengthens Serco's "citizen services capabilities in the US and internationally".

GlaxoSmithKline said positive results from clinical trials could see HIV patients take monthly treatments instead of daily dosages.

Two clinical trials revealed that a once a month, two-drug treatment was just as effective as a daily, three drug regimen.

If approved, the monthly treatment could alleviate the burden on HIV patients.

The studies were carried out on drugs developed by GSK's subsidiary ViiV Healthcare and Janssen Pharmaceutical Companies of pharmaceutical giant Johnson & Johnson.